GlassScriptPhysician profile
Niccole Mambu Oswald
NPI 1285628180
$2,729.27
in general payments reported to CMS, 2019-2025
23 companies · $69.31 in 2025
The $69.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $87.31 · 2021: $336 · 2022: $622 · 2023: $823 · 2024: $343 · 2025: $69.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $645.80 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $348.21 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $231.71 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $199.08 | 2019-2025 | |
| Abbvie INC. | $192.59 | 2021-2024 | |
| Astellas Pharma US INC | $186.01 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $153.51 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.66 | 2020-2023 | Jardiance |
| Amgen INC. | $143.23 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $85.55 | 2020-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $82.81 | 2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $50.41 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $45.85 | 2021-2022 | |
| Exact Sciences Corporation | $36.49 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $34.39 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $32.46 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.98 | 2022 | |
| Almatica Pharma LLC | $20.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.15 | 2019 | |
| Vertos Medical, INC. | $14.83 | 2019 | |
| Amarin Pharma, INC. | $12.80 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niccole Oswald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.